Comparing Calliditas Therapeutics AB (publ) (NASDAQ:CALT) & Viracta Therapeutics (NASDAQ:VIRX)

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Viracta Therapeutics (NASDAQ:VIRX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for Calliditas Therapeutics AB (publ) and Viracta Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0	0	0	0	0.00
Viracta Therapeutics	0	2	1	0	2.33

Viracta Therapeutics has a consensus target price of $1.75, suggesting a potential upside of 17,793.66%. Given Viracta Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Viracta Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Volatility & Risk

Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Comparatively, Viracta Therapeutics has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500.

Earnings & Valuation

This table compares Calliditas Therapeutics AB (publ) and Viracta Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60 billion	0.74	-$43.96 million	($1.85)	-21.62
Viracta Therapeutics	N/A	N/A	-$51.06 million	($1.10)	-0.01

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Viracta Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Viracta Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 31.4% of Viracta Therapeutics shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Comparatively, 10.7% of Viracta Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Calliditas Therapeutics AB (publ) and Viracta Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Viracta Therapeutics	N/A	-1,899.61%	-114.21%

Summary

Viracta Therapeutics beats Calliditas Therapeutics AB (publ) on 8 of the 13 factors compared between the two stocks.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.

About Viracta Therapeutics

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.